Blood Cover Letter: What Editors Actually Need to See
Blood editors are screening for real hematology consequence, not just technically solid blood research. A strong cover letter makes that field-level case obvious fast.
Readiness scan
Before you submit to Blood, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Blood at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- Blood's scope and readership determine whether the journal is a useful target.
- Scope specificity matters more than headline metrics for most manuscript decisions.
- Acceptance rate of ~20% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope, borderline fit rarely improves after submission.
- If timeline matters: Blood takes ~30 days. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
How to use this page well
These pages work best when they behave like tools, not essays. Use the quick structure first, then apply it to the exact journal and manuscript situation.
Question | What to do |
|---|---|
Use this page for | Getting the structure, tone, and decision logic right before you send anything out. |
Most important move | Make the reviewer-facing or editor-facing ask obvious early rather than burying it in prose. |
Common mistake | Turning a practical page into a long explanation instead of a working template or checklist. |
Next step | Use the page as a tool, then adjust it to the exact manuscript and journal situation. |
Quick answer: Blood is the American Society of Hematology's flagship research journal. A strong cover letter makes the hematology consequence visible immediately: what the manuscript establishes, which evidence makes the result credible, and why Blood readers, not merely a narrower subspecialty, need the finding. Do not lead with impact metrics, generic novelty, or reviewer logistics.
Evidence basis: We rechecked Blood's current author guidance and journal scope on August 15, 2026. The requirements are sourced; the letter test is Manusights guidance.
Make the Blood fit case in three moves
Move | What to write | What weakens it |
|---|---|---|
Hematology problem | Name the biological or clinical decision the paper resolves | A generic statement that blood disease matters |
Decisive evidence | Identify the result, comparator, and boundary that carry the claim | A catalog of methods or every secondary finding |
Blood readership | Explain why the consequence matters to this journal's broad hematology audience | Prestige, impact-factor, or flattery language |
Required context | Add originality, conflicts, related work, and special handling information when applicable | Boilerplate that contradicts portal disclosures |
Move | Evidence to state | Weak version |
|---|---|---|
Hematology problem | Name the biological or clinical question for Blood readers | A generic biomedical opening |
Consequential result | State the finding and the evidence that makes it credible | “Novel” without a comparison or consequence |
Journal fit | Explain who in hematology will use or build on the result | Prestige or impact-factor language |
Then reconcile the letter with the title, abstract, first figure, and declarations. If any artifact implies a different central claim, fix the manuscript package first. A clear letter helps editors inspect fit; it cannot determine the decision.
The hematology consequence test
Use four sentences to test the letter before polishing it. Each should advance the editorial case rather than repeat the abstract.
Sentence job | What to make explicit | Weak substitute |
|---|---|---|
Hematology problem | The disease, cell system, coagulation process, or clinical decision | A generic unmet-need opening |
New finding | The specific biological or clinical advance | “Novel findings” without the result |
Decisive support | The experiment, cohort, comparison, or validation that carries the claim | A list of methods |
Blood relevance | Why the result changes hematology understanding or practice | Journal prestige or audience size |
If those four sentences cannot stand together without qualification, narrow the claim or repair the evidence before submission.
What Blood Editors Screen For
Criterion | What They Want | Common Mistake |
|---|---|---|
Scope fit | Real hematology consequence, clinical or translational relevance to blood disease | Submitting technically solid work without connecting it to hematology practice |
Novelty claim | A clear hematology advance stated directly | Leading with submission logistics or reviewer suggestions instead of the science |
Significance | Field-shaping result that matters to Blood readers broadly | Niche findings that only matter inside one narrow hematology subfield |
Journal distinction | Clear reason for Blood vs. a narrower leukemia, thrombosis, or transplant journal | Failing to explain why the work reaches beyond one subspecialty |
Tone | Credible hematology consequence without overclaiming clinical impact | Unsupported claims about changing patient care |
What the official sources do and do not tell you
The official Blood pages explain submission workflow and required reviewer suggestions, but they do not provide one ideal cover-letter formula.
What the journal model makes clear:
- the manuscript should matter to the broader hematology field
- the editor needs to understand the hematology consequence quickly
- the letter should clarify why the paper belongs in Blood rather than in a narrower lab, leukemia, thrombosis, or transplant title
- medical writer disclosure is mandatory in the cover letter: any involvement of medical writers or researchers must be explicitly disclosed to the editor-in-chief
That means the cover letter should not read like a submission checklist with a little science added in.
What the editor is really screening for
At triage, the editor is usually asking:
- what is the hematology advance?
- why does it matter to Blood readers specifically?
- is this a field-shaping hematology paper or a stronger fit for a narrower venue?
- does the manuscript look complete enough to survive serious review?
That is why the first paragraph should state the blood-disease or hematology result directly rather than leading with process details.
What a strong Blood cover letter should actually do
A strong letter usually does four things:
- states the hematology result directly in the first sentence
- explains the field consequence in plain language
- shows why Blood is the right audience (broader than one subspecialty)
- discloses any medical writer involvement and confirms ASH compliance
A practical template you can adapt
Dear Editor,
We submit the manuscript "Clonal Platelet Signaling Predicts Thrombosis
Risk in Myeloproliferative Neoplasms" for consideration at Blood.
This study addresses thrombosis risk stratification in
myeloproliferative neoplasms. We show that a clonal platelet-signaling
signature identifies patients with elevated thrombotic risk beyond
standard clinical variables.
The manuscript is a strong fit for Blood because the advance matters to
readers interested in malignant hematology, thrombosis, and risk
stratification, not just to a narrow subspecialty slice.
No medical writer contributed to the preparation of this manuscript.
This work is original, not under consideration elsewhere, and approved by
all authors.
Sincerely,
Corresponding authorMistakes that make these letters weak
The common failures are:
- leading with reviewer-suggestion requirements instead of the scientific fit
- describing the work like a methods paper rather than a hematology advance
- claiming clinical impact the manuscript does not actually support
- copying the abstract instead of helping editorial routing
- writing a generic hematology letter that could fit any specialty journal
- omitting the mandatory medical writer disclosure when applicable
These mistakes usually tell the editor the manuscript is either overclaimed or not yet framed around its strongest hematology value.
Blood-specific cover letter requirements (from ASH author guidelines)
Hematologic significance must be explicit. Blood editors see many papers that use blood cells without addressing hematologic questions. Your cover letter must make the hematologic focus unmistakable. Papers about general signaling that happen to use T cells belong at Immunity or JEM, not Blood.
Medical writer disclosure. Any involvement of medical writers or researchers must be disclosed to the Editor-in-Chief in the cover letter. This is not just an acknowledgement, it's a cover letter requirement.
Blood values papers that close questions, not just open them. Editors particularly look for work that resolves significant open questions in hematology rather than generating new questions without resolution.
Translational bridge matters. If your mechanistic findings suggest new therapeutic approaches or diagnostic strategies, state this clearly. Blood bridges basic and clinical hematology, and the cover letter should reflect both dimensions when possible.
Publication costs
Venue | Model | Typical cost |
|---|---|---|
Blood (subscription) | No page charges | $0 |
Blood (gold OA) | Optional | ~$4,000 (ASH) |
Blood Advances | Mandatory OA | ~$3,000 |
Leukemia | Subscription | $0; ~$4,000 OA |
JCI | Fully OA, no APC | $0 |
Blood does not charge page or color charges for subscription publication. Blood Advances (~$3,000 mandatory OA) is the natural cascade within ASH for papers that don't clear Blood's bar.
A Blood cover letter and desk-rejection risk check scores fit against the journal's editorial bar.
How Blood compares to adjacent hematology journals
Feature | Blood | Blood Advances | Leukemia |
|---|---|---|---|
Primary scope | Broad hematology: clinical and translational, field-shaping advances | Hematology work that is strong but narrower in scope or impact | Leukemia, lymphoma, and myeloid disease biology and treatment |
Published acceptance denominator | Not comparable on the official pages reviewed | Not comparable on the official pages reviewed | Not comparable on the official pages reviewed |
Key frame for cover letter | Why does this matter to hematologists beyond one narrow disease or mechanism? | Strong hematology work with clear but more focused consequence | Why does this advance leukemia or lymphoma biology specifically? |
Preferred study types | Mechanistic + translational hematology with field-shaping consequence | Focused clinical or translational hematology studies | Disease-specific biology and clinical studies in leukemia/lymphoma |
Ideal distinction argument | Result changes how hematologists think about a disease, mechanism, or risk category broadly | Result is important but the primary audience is a defined hematology subspecialty | Result specifically advances leukemia or lymphoma biology or management |
What should drive the submission decision instead
Before polishing the letter further, make sure the journal choice is right.
The better next reads are:
If the paper truly matters to clinical or translational hematology, the cover letter should only need to make that obvious. If the work is more narrowly scoped, a different journal may serve it better. Blood Advances (~$3,000 mandatory OA) is the natural cascade within ASH for papers that don't clear Blood's selectivity bar.
Practical verdict
The strongest Blood cover letters are short, hematology-first, and honest about the scale of the field consequence. They do not waste their most important space on submission mechanics.
State the hematology advance plainly, show why Blood readers should care, and let the submission details stay secondary. A Blood cover letter framing check is a direct way to pressure-test whether your framing already does that before submission.
Evidence risks to test for Blood submissions
For manuscripts targeting Blood, five cover letter patterns generate the most consistent desk rejections, even when the underlying hematology science is technically rigorous.
Cover letter leads with reviewer-suggestion mechanics instead of hematology advance. Blood requires reviewer suggestions in the submission system, and many authors spend the first paragraph of their cover letter discussing reviewer selection criteria, conflict-of-interest justifications for suggested reviewers, or instructions for exclusions. The editor reads the cover letter to assess hematology significance before the submission system is consulted for reviewer logistics.
A cover letter that opens with reviewer management rather than the hematology advance signals that the author has prioritized administrative compliance over scientific framing. The first paragraph should state what was found and why it matters to hematology. The reviewer suggestions belong in the submission system fields, not in the opening paragraph of the letter.
Blood cell biology paper without hematologic disease connection. Blood covers clinical and translational hematology, not general immunology or cell biology that happens to use blood cells as a model system. A paper that investigates T cell activation, B cell receptor signaling, or myeloid differentiation without connecting the finding to a hematologic disease question or therapeutic consequence is a paper for Immunity, the Journal of Experimental Medicine, or a specialty immunology journal.
The Blood cover letter must make the hematologic disease relevance unmistakable: what blood disease does this finding speak to, how does it change understanding of disease pathogenesis, or what treatment implication does it carry? General signaling biology using hematopoietic cells is not sufficient.
Overclaiming clinical impact without clinical data. Blood bridges basic and clinical hematology, and editors value cover letters that state translational relevance when the mechanistic findings suggest therapeutic or diagnostic consequences. However, a cover letter that states the paper "establishes a new therapeutic approach for patients with X" when the manuscript contains only cell line or mouse data is overclaiming.
Blood reviewers are often clinician-scientists who recognize the distance between mechanistic findings and clinical translation. The cover letter should calibrate the clinical claim to the evidence: "our findings suggest a therapeutic vulnerability that warrants investigation in clinical models" for preclinical work, not "we demonstrate a new treatment strategy."
Letter that works for any hematology journal without a Blood-specific breadth argument. Blood is the ASH flagship and serves the full hematology community across malignant and non-malignant hematology, hemostasis, thrombosis, and hematopoiesis. Papers that are genuinely important within one narrow hematology subspecialty are often better served by more focused journals: Leukemia, Haematologica, or Journal of Thrombosis and Haemostasis.
The Blood cover letter must make a breadth argument: why does this finding matter to hematologists working outside the author's exact subspecialty? If the best argument is "this is interesting to specialists in X," Blood may not be the right journal.
Missing mandatory medical writer disclosure. ASH requires that any involvement of medical writers, contract researchers, or professional scientific editors in manuscript preparation be disclosed to the editor-in-chief in the cover letter. This is an explicit cover letter requirement, not a general author declaration.
It applies to medical communications agencies, academic writing services, and individual freelance scientific editors who contributed substantively to the manuscript. Omitting this disclosure when applicable creates a compliance issue that the editorial office will flag. The cover letter should include a clear statement: either confirming no medical writer was involved, or naming the individual or agency and describing their contribution.
A Blood cover letter framing check is the fastest way to verify that your framing meets the editorial bar before submission.
Submit Now If / Think Twice If
Submit to Blood if:
- the finding has genuine hematology consequence: it changes how hematologists understand a disease, mechanism, or management question
- the breadth argument is honest: the advance matters to hematologists beyond one narrow subspecialty
- the cover letter opens with the hematology advance, not with reviewer logistics or submission mechanics
- mandatory disclosures are ready: medical writer involvement, conflicts of interest, data availability
- the manuscript is not a better fit for Blood Advances (sound hematology that does not clear Blood's selectivity bar)
Think twice if:
- the paper is primarily basic immunology or cell biology without a specific hematologic disease connection (Immunity or JEM is more appropriate)
- Blood Advances (~7.7) is the natural home for solid hematology work that does not require Blood's flagship selectivity
- the Journal of Clinical Investigation (~13.6) is a better fit for mechanistic disease work with breadth beyond hematology
- Leukemia (~8.8) or Haematologica is more appropriate for focused malignant hematology work
- the clinical claim requires in vivo or patient data the current manuscript does not contain
Readiness check
Run the scan while Blood's requirements are in front of you.
See how this manuscript scores against Blood's requirements before you submit.
How Blood Compares for Cover Letter Strategy
Feature | Blood | Blood Advances | Journal of Clinical Investigation | Leukemia |
|---|---|---|---|---|
2025 JIF (2026 JCR release) | ~23.9 | ~7.7 | ~14.3 | ~8.8 |
First-screen emphasis | Broad hematology consequence | Complete focused hematology contribution | Mechanism with cross-disease consequence | Malignant-hematology depth |
Cover letter emphasis | Hematology field consequence with breadth across blood diseases and translational relevance | Sound hematology without flagship-level breadth requirement; mandatory OA | Disease mechanism with translational consequence across internal medicine | Malignant hematology: leukemia, lymphoma, myeloma, MDS |
Best for | Field-shaping hematology findings with broad relevance across blood diseases | Solid hematology work at lower selectivity with open-access publishing | Mechanistic disease biology with broader internal medicine implications | Focused malignant hematology with mechanistic or translational depth |
Official and authoritative sources accessed 2026-08-17.
- Blood author guidelines, ASH Publications.
- Blood journal page, ASH Publications.
- ASH publishing policies, ASH Publications.
- Clarivate Journal Citation Reports (2026 release for the 2025 Journal Impact Factor), Clarivate.
Submit If / Think Twice If
Submit if:
- the hematology advance has consequence beyond one narrow disease subtype or mechanism, reaching Blood's broad readership across clinical and translational hematology
- the cover letter can state the hematology result and its field consequence in two sentences without subspecialty setup
- the paper answers a significant open question in hematology rather than generating new questions without resolution
- a translational bridge is present: mechanistic findings connect to therapeutic approaches, risk stratification, or diagnostic strategies in hematology
Think twice if:
- the main contribution is strong data from a specialized niche where the primary audience is thrombosis specialists, transplant hematologists, or researchers in one narrow subtype (Blood Advances may be the cleaner fit)
- the paper uses blood cells as a model system without addressing hematologic questions specifically (Immunity or JEM may be better targeted)
- the clinical impact claim is not supported by the evidence level in the manuscript
- the cover letter currently opens with reviewer suggestions or submission logistics before stating the hematology science
Frequently asked questions
It should state the hematology advance clearly and explain why the result matters to the Blood readership rather than just listing submission logistics.
A common mistake is focusing on reviewer-suggestion mechanics or general novelty without making a strong case for why the manuscript matters to clinical or translational hematology.
No. Editors want a credible hematology consequence, but unsupported claims about changing care usually weaken trust rather than helping the manuscript.
No. A short, direct letter is usually stronger because editors need to judge hematology relevance and fit quickly.
Free guide
A cover letter is a routing note, not a sales pitch.
The editor is deciding one thing from it: is this worth my reviewers time, and does it belong here. The guide is a one-page skeleton written to that decision, so the letter answers it in the first minute rather than restating your abstract.
Final step
Submitting to Blood?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal Blood
Private API processing. Your manuscript is not used to train models.
See example reportsPut the guidance to work
Move from draft advice to a practical manuscript pass.
Choose the reporting framework first, then use the final checklist when the manuscript and submission files are ready to travel together.
Where to go next
Start here
Same journal, next question
- Blood Submission Guide: How to Get Published in ASH's Flagship
- How to Avoid Desk Rejection at Blood
- Blood Review Time: What to Expect From Submission to Decision
- Blood Submission Process: What Happens From Upload to First Decision
- Blood Acceptance Rate 2026: How Selective Is the ASH Flagship?
- Blood (ASH) 'Under Review': What Each Status Means and When to Expect a Decision